Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1992-10-23
1995-04-18
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514172, 514173, 514176, 514180, 514182, A61K 3156, A61K 3158
Patent
active
054079268
ABSTRACT:
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and an angiostatic steroid. The angiostatic steroid substantially prevents any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent anti-inflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure.
REFERENCES:
patent: 4617299 (1986-10-01), Knepper
patent: 4686214 (1987-08-01), Boltralik
patent: 4876250 (1989-10-01), Clark
Gillman et al., "Goodman & Gillman's The Pharmacological Basis of Therapeutics", 7th Ed. 1473-1474 (1985).
McKerns, Steroid Hormones and Metabolism, Appleton-Century-Croffs, New York:1969, Chapter 8, pp. 93-103.
Kitazawa, Y., "Increased Intraocular Pressure Induced by Corticosteroids," Am. Journal of Oph., 82:492-493 (1976).
Cantrill et al., "Comparison of In Vitro Potency of Corticosteroids with Ability to Raise Intraocular Pressure," Am. Journal of Oph., 79:1012-1016 (1975).
Mindel et al., "Comparative Ocular Pressure Elevation by Medrysone, Fluorometholone, and Dexamethasone Phosphate," Arch Ophthal, 98:1577-1578 (1980).
Southren et al., "Intraocular Hypotensive Effect of a Topically Applied Cortisol Metabolite: 3.alpha., 5.beta. Tetrahydrocortisol," Investigative Ophthalmology & Visual Science, 28:901-903 (1987).
Treister et al., "Intraocular Pressure and Outflow Facility," Arch. Ophthal., 83:311-318 (1970).
Meyer et al., "Influence of Norethynodrel With Mestranol on Intraocular Pressure in Glaucoma," Arch Ophthal., 75:771-773 (1966).
Lamble et al., "Some Effects of Progestogens, Oestrogens and Androgens on the Ocular Tension of Rabbits and Owl Monkeys," Exp. Eye Res. 26:599-610 (1978).
Knepper et al., "Intraocular Pressure & Glycosaminoglycan Distribution in the Rabbit Eye: Effect of Age and Dexamethosone," Exp. Eye Res., 27:567-575 (1978).
Hester et al., "Steroid-Induced Ocular Hypertension in the Rabbit: A Model Using Subconjunctival Injections," J. Ocular Pharmacology, 3(3):185-189 (1987).
Crum et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment," Science, 230:1375-1378 (Dec., 1985).
Ingber et al., "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution," Endocrinology, 119(4):176-1775 (1986).
Folkman et al., "Angiostatic Steroids," Ann. Surg., 206(3):374-382 (1987).
Knepper et al. "Glycosaminoglycans and Outflow Pathways of the Eye and Brain," Pediatric Neuroscience, 12:240-251 (1985-86).
Knepper et al. "Effect of Dexamethasone, Progesterone, and Testosterone on IOP & GaGs in the Rabbit Eye," Invest. Ophth. & Vis. Science, 26:1093-1100 (Aug., 1985).
Rohen, Johanness W. "Why is Intraocular Pressure Elevated in Chronic Simple Glaucoma?", Ophthalmology, 90(7):758-764 (1983).
Southren et al. "5.beta.-Dihydrocortisol: Possible Mediator of the Ocular Hypertension in Glaucoma," Invest. Ophth. & Vis. Science, 26:393-395 (Mar., 1985).
Alcon Laboratories Inc.
Brown Gregg C.
Cheng Julie J. L.
Fay Zohreh
LandOfFree
Ophthalmic composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-67401